AMRX vs ALKS
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
AMRX · Amneal Pharmaceuticals$20.14 ▲ 3.55%
ALKS · Alkermes$45.90 ▲ 3.05%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- AMRX +75.4%
- ALKS +40.6%
Head to head
| Metric | AMRX | ALKS |
|---|---|---|
| Price | $20.14 | $45.90 |
| Change today | ▲ 3.55% | ▲ 3.05% |
| Market cap | $6.43B | $7.71B |
| Return, 3 months | +12.6% | -7.1% |
| Return, year to date | +59.8% | +64.0% |
| Return, 1 year | +77.1% | +39.6% |
| P/E (TTM) | 50.4 | – |
| P/B | 12.1 | 4.1 |
| P/E percentile vs own 5y | 61st | 97th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +9.9% | +27.0% |
| Net profit growth (YoY) | +95.5% | -99.4% |
| Gross margin | 39.3% | 84.6% |
| Operating margin | 15.4% | 8.6% |
| Net margin | 5.0% | 4.0% |
| Return on equity | – | 3.9% |
| Analyst target vs. price | +18.3% | +30.3% |
| Analyst buy share | 100% | 73% |
| RSI (14) | 51 | 60 |
| 30-day volatility | 33.2% | 31.6% |
| Max drawdown, 1 year | -22.3% | -29.2% |
| Trend read | Leaning bullish | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ALKS is the largest of the group by market value.
- AMRX has returned the most over the past year.
- ALKS is growing revenue fastest.
- AMRX keeps the most profit per dollar of sales.
- ALKS has been the calmest stock over the last 30 days.